Information Provided By:
Fly News Breaks for November 8, 2019
Nov 8, 2019 | 07:14 EDT
Stifel analyst David Grossman said that although he sees several positives in Tabula Rasa HealthCare's quarterly report, the near-term focus will be the cancellation of a $10M "adherence" contract that resulted in 2019 guidance cut. While the cancellation is disappointing, he doesn't read it as an indication of fundamental weakness and would "act opportunistically" on any sustained weakness in the shares, the analyst tells investors. He lowered his price target on Tabula Rasa shares to $65 from $75 but maintains a Buy rating on the stock.
News For TRHC From the Last 2 Days
There are no results for your query TRHC